FasterCures, a center of the Milken Institute, has long supported policies that accelerate new, cutting-edge biomedical innovations to patients. The center was instrumental in gaining support for the 21st Century Cures Act in 2016, and looks forward to championing Cures 2.0, which contains numerous provisions critical to FasterCures and its patient community.
Statement attributable to Esther Krofah, executive director of FasterCures and the Center for Public Health, Milken Institute:
“We applaud Representatives Diana DeGette and Fred Upton’s introduction today of 21st Century Cures 2.0, landmark legislation which will bring forward new solutions to some of the most pressing challenges facing biomedical innovation. This bill addresses the need for greater diversity in clinical trials, facilitates the development of cell and gene therapies, and establishes a new approach to addressing antimicrobial resistance, all critical issues to patient communities. The legislation also calls for the creation of ARPA-H, an incubator for cutting-edge biomedical research within the National Institutes of Health, which will accelerate the discovery of next-generation treatments and cures. We look forward to working with Congress as this legislation makes its way through the committee process.”